A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy-Reference-Cited by-同舟云学术

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Published:2014-07 Issue:7 Volume:25 Page:1328-1333
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Aapro M.,Rugo H.,Rossi G.,Rizzi G.,Borroni M.E.,Bondarenko I.,Sarosiek T.,Oprean C.,Cardona-Huerta S.,Lorusso V.,Karthaus M.,Schwartzberg L.,Grunberg S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/7/1328/16697971/mdu101.pdf

Reference13 articles.

1. Best practice management of CINV in oncology patients: I. physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches;Frame;J Support Oncol,2010

2. Update and new trends in antiemetic therapy: the continuing need for novel therapies;Feyer;Ann Oncol,2011

3. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference;Roila;Ann Oncol,2010

4. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy;Warr;J Clin Oncol,2005

5. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER);Aapro;Ann Oncol,2012

Cited by 211 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can we counterbalance restricted access to innovation through specialized breast cancer care? The REAL-NOTE study;The Breast;2024-12

2. Adequate antiemetic treatment in patients receiving antitumor drug therapy;Head and Neck Tumors (HNT);2024-08-03

3. Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database;Frontiers in Pharmacology;2024-07-31

4. Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review;European Journal of Haematology;2024-07-29

5. Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis;Frontiers in Oncology;2024-07-26